205 related articles for article (PubMed ID: 34575033)
1. Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer.
Nordeen SK; Su LJ; Osborne GA; Hayman PM; Orlicky DJ; Wessells VM; van Bokhoven A; Flaig TW
Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575033
[TBL] [Abstract][Full Text] [Related]
2. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
Denmeade SR; Isaacs JT
Prostate; 2010 Oct; 70(14):1600-7. PubMed ID: 20607766
[TBL] [Abstract][Full Text] [Related]
3. Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer.
Denmeade SR; Sena LA; Wang H; Antonarakis ES; Markowski MC
Oncologist; 2023 Jun; 28(6):465-473. PubMed ID: 37027449
[TBL] [Abstract][Full Text] [Related]
4. Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions.
Mohammad OS; Nyquist MD; Schweizer MT; Balk SP; Corey E; Plymate S; Nelson PS; Mostaghel EA
Cancers (Basel); 2017 Dec; 9(12):. PubMed ID: 29210989
[TBL] [Abstract][Full Text] [Related]
5. Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire.
Nabavi N; Mahdavi SR; Ardalan MA; Chamanara M; Mosaed R; Lara A; Bastos D; Harsini S; Askari E; Velho PI; Bagheri H
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509723
[TBL] [Abstract][Full Text] [Related]
6. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Teply BA; Wang H; Luber B; Sullivan R; Rifkind I; Bruns A; Spitz A; DeCarli M; Sinibaldi V; Pratz CF; Lu C; Silberstein JL; Luo J; Schweizer MT; Drake CG; Carducci MA; Paller CJ; Antonarakis ES; Eisenberger MA; Denmeade SR
Lancet Oncol; 2018 Jan; 19(1):76-86. PubMed ID: 29248236
[TBL] [Abstract][Full Text] [Related]
7. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
Karantanos T; Corn PG; Thompson TC
Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
[TBL] [Abstract][Full Text] [Related]
9. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
Westaby D; Viscuse PV; Ravilla R; de la Maza MLDF; Hahn A; Sharp A; de Bono J; Aparicio A; Fleming MT
Am Soc Clin Oncol Educ Book; 2021 Jun; 41():e190-e202. PubMed ID: 34061561
[TBL] [Abstract][Full Text] [Related]
10. The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression.
Gao L; Han B; Dong X
Front Oncol; 2022; 12():905398. PubMed ID: 35832549
[TBL] [Abstract][Full Text] [Related]
11. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy.
Sena LA; Wang H; Lim ScM SJ; Rifkind I; Ngomba N; Isaacs JT; Luo J; Pratz C; Sinibaldi V; Carducci MA; Paller CJ; Eisenberger MA; Markowski MC; Antonarakis ES; Denmeade SR
Eur J Cancer; 2021 Feb; 144():302-309. PubMed ID: 33383350
[TBL] [Abstract][Full Text] [Related]
12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
13. Bipolar androgen therapy (BAT): A patient's guide.
Denmeade S; Antonarakis ES; Markowski MC
Prostate; 2022 May; 82(7):753-762. PubMed ID: 35357024
[TBL] [Abstract][Full Text] [Related]
14. The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications.
Kumar R; Sena LA; Denmeade SR; Kachhap S
Nat Rev Urol; 2023 May; 20(5):265-278. PubMed ID: 36543976
[TBL] [Abstract][Full Text] [Related]
15. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Bipolar Androgen Therapy for Castration-Resistant Prostate Cancer: In Vitro and In Vivo Studies.
Yu J; Lim JE; Song W
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255286
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
18. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
19. Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level.
Rouleau M; Neveu B; Caron P; Morin F; Toren P; Lacombe L; Turcotte V; Lévesque É; Guillemette C; Pouliot F
J Urol; 2022 Dec; 208(6):1214-1225. PubMed ID: 36102111
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer.
Moses M; Koksal U; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Sartor AO; Barata P
Oncotarget; 2020 Jan; 11(1):15-21. PubMed ID: 32002120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
